Compare

Pulmatrix, Inc. vs Lexaria Bioscience Corp. vs Cadrenal Therapeutics, Inc. vs Protagenic Therapeutics, Inc.new

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearPulmatrix, Inc.
PULM
Lexaria Bioscience Corp.
LEXX
Cadrenal Therapeutics, Inc.
CVKD
Protagenic Therapeutics, Inc.new
PTIXRevenue covers only part of its income (partial revenue)
Year ended2025-12-312025-08-312025-12-312026-03-31
Revenuen/a$705.9Kn/an/a
Revenue growth (YoY)n/a+52.0%n/an/a
Gross marginn/a99.6%n/an/a
Operating marginn/an/mn/an/a
Net marginn/an/mn/an/a
Net income-$5.16M-$11.90M-$13.24M$1.37M
EPS (Diluted)-$1.41-$0.66-$6.64$0.59
Operating cash flow-$5.43M-$10.45M-$12.60M-$2.81M
Free cash flown/a-$10.48M-$12.61M-$2.81M
Cash & equivalents$4.09Mn/a$4.01Mn/a
Total assets$4.14M$4.18M$4.33M$3.65M
Total liabilities$329.0K$1.57M$1.59M$1.03M
Shareholders' equity$3.81M$2.99M$2.74M$2.62M
Return on year-end equity-135.5%-398.1%-483.3%52.2%
Shares outstanding3.65M19.56M2.34M1.81M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearPulmatrix, Inc.Lexaria Bioscience Corp.Cadrenal Therapeutics, Inc.Protagenic Therapeutics, Inc.new
Latest$7.81M
Ended 2024-12-31
$705.9K
Ended 2025-08-31
n/an/a
1 year earlier$7.30M
Ended 2023-12-31
$464.3K
Ended 2024-08-31
n/an/a
2 years earlier$6.07M
Ended 2022-12-31
$226.2K
Ended 2023-08-31
n/an/a
3 years earlier$5.17M
Ended 2021-12-31
$255.4K
Ended 2022-08-31
n/an/a
4 years earlier$12.63M
Ended 2020-12-31
$722.7K
Ended 2021-08-31
n/an/a